PBPK model of carbamazepine and its metabolite for bioequivalence assessment: prioritizing early exposure and single-dose study designs
- DOI
- 10.1016/j.ejpb.2026.115232
- Published
- 2026-11
- Container
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejpb.2026.115232,
title = {PBPK model of carbamazepine and its metabolite for bioequivalence assessment: prioritizing early exposure and single-dose study designs},
author = {Javier Zarzoso-Foj and Marina Cuquerella-Gilabert and Javier Reig-López and Víctor Mangas-Sanjuán and Alfredo García-Arieta},
year = {2026},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
doi = {10.1016/j.ejpb.2026.115232},
url = {https://doi.org/10.1016/j.ejpb.2026.115232}
}RIS
TY - JOUR TI - PBPK model of carbamazepine and its metabolite for bioequivalence assessment: prioritizing early exposure and single-dose study designs AU - Javier Zarzoso-Foj AU - Marina Cuquerella-Gilabert AU - Javier Reig-López AU - Víctor Mangas-Sanjuán AU - Alfredo García-Arieta PY - 2026 JO - European Journal of Pharmaceutics and Biopharmaceutics DO - 10.1016/j.ejpb.2026.115232 UR - https://doi.org/10.1016/j.ejpb.2026.115232 ER -
APA
Zarzoso-Foj, J., Cuquerella-Gilabert, M., Reig-López, J., Mangas-Sanjuán, V., & García-Arieta, A. (2026). PBPK model of carbamazepine and its metabolite for bioequivalence assessment: prioritizing early exposure and single-dose study designs. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115232
Source records
- crossref · retrieved 2026-09-25T03:05:22.374Z